Non-Hodgkin's Lymphoma Research Report States Number of B-cell NHL cases will Reach 129,179 by 2024 in 7MM : Latest Press Release by MarketResearchReports.Biz

MarketResearchReports.Biz presents this most up-to-date research on "EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024". has added a new research report, titled “EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast To 2024,” to its vast database. The research report on non-Hodgkin lymphoma or NHL explains the nature of the disease with a complete chapter on its epidemiology. This chapter explains the patterns, causes, and effects of NHL on the overall health of the patient. It also studies the background of the disease and risk factors.

Non-Hodgkin lymphoma is a type of cancer that starts in cells called lymphocytes, which are an integral part of the human immune system. Lymphocytes are found in the lymph nodes and other lymphoid tissues such as in bone marrow and the spleen. Non-Hodgkin lymphoma (NHL) is a group of blood cancers that develop in the lymphatic system. This disease negatively impacts the immune system with an uncontrollable growth of malignant white blood cells, which, over a period of time, depletes the body’s ability to fight against infections and other incursions. So far, NHL has been categorized into three types, namely, T-cell, B-cell, and natural killer lymphocyte lymphomas.

Download Sample copy of this Report at

The report on NHL sheds light on the four subtypes of B-cell NHL, namely, diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma, follicular lymphoma, and mantle cell lymphoma. Research suggests that occurrence of NHL is common amongst white men than in women and its chances increase with age.

According to the forecast published in the research report, the number of B-cell NHL cases in the 7MM, namely France, Germany, Italy, Japan, Spain, the UK and the US, was 104,854 in 2014 and is expected to reach 129,179 by 2024. This growth will be registered at an annual growth rate of 2.32% from 2015 to 2024. Of all these regions, the US will witness the highest number of B-cell NHL cases. This region alone is expected to have a growth rate of 36% all through 2024 to reach a figure of 57,724. Furthermore, each of the aforementioned countries will witness a rise in the number of cases in the coming 10 years.

View Press Release Report at:

To analyze the growing incidence of NHL, epidemiologists have collated data from peer-reviewed journals, new items, and country-specific disease databases to create a well-researched document for the readers. The report offers a detailed 10-year forecast of the NHL cases of marginal zone lymphoma, mantle cell lymphoma, follicular lymphoma, and DLBCL in the seven major markets of the world.

The country-specific analysis of NHL helps in establishing a meaningful comparison of the elements influencing the B-cell NHL incidence in the 7MM. Additionally, the research report also provides a segmentation of the disease on the basis of age, sex, and the sub-types, thereby highlighting the proliferation of B-cell NHL research and market growth in the major markets.